Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

Sara Ghorashian, MD PhD FRCPath, Anne Marijn Kramer, MD, Sarah Jayne Albon, BSc, MSc, Catherine Irving, BSc, Lucas Chan, PhD, Fernanda Castro, PhD, Bilyana Popova, Kim Champion, PhD, Gary Wright, Hong Zhan, PhD, Waseem Qasim, MBBS PhD, Robert Wynn, Rachael Hough, MD BMBS, FRCP, FRCPath, Farzin Farzaneh, Martin A Pule, MD PhD, Persis J Amrolia, Professor

Blood (2016) 128 (22): 4026.

https://doi.org/10.1182/blood.V128.22.4026.4026

Published: 2016

Journal Articles

Construction and Pre-Clinical Evaluation of a New Anti-CD19 Chimeric Antigen Receptor

Anne Marijn Kramer, MD, Sara Ghorashian, MD PhD FRCPath, Gordon Weng-Kit Cheung, MSc, Winston Vetharoy, BVSc, Dale Moulding, PhD, Leila Mekkaoui, MSc, Shimobi Onuoha, PhD, Persis J Amrolia, Professor, Martin A Pule, MD PhD

Blood (2016) 128 (22): 1627.

https://doi.org/10.1182/blood.V128.22.1627.1627

Published: 2016

Journal Articles

Novel Humanised ROR1 Chimeric Antigen Receptors for the Treatment of Haematological Malignancies

Satyen Harish Gohil, MBBS MRCP FRCPath, Marco Della Peruta, PhD, Solange R Paredes-Moscosso, Micaela Harrasser, Gordon Weng-Kit Cheung, MSc, David M Davies, PhD, Martin A Pule, MD PhD, Amit C Nathwani, MD PhD

Blood (2016) 128 (22): 3361.

https://doi.org/10.1182/blood.V128.22.3361.3361

Published: 2016

Journal Articles

An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo

Lydia Sarah Hui Lee, MBBS, MRCP, MRCPath, BSc, Benjamin Owen Draper, BSc, MSc, Neil Chaplin, BSc, MSc, Brian Philip, PhD, Melody Chin, BSc, MSc, Daria Galas-Filipowicz, BSc, MSc, Simon Thomas, PhD, Evangelia Kokalaki, BSc, MSc, James Francis, PhD, Kwee L Yong, Martin A Pule, MD PhD

Blood (2016) 128 (22): 379.

https://doi.org/10.1182/blood.V128.22.379.379

Published: 2016

Journal Articles

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

Paul Michael Maciocia, BSc,MBBS,MRCP, Patrycja Wawrzyniecka, MSc, Brian Philip, PhD, Ida Ricciardelli, PhD, Ayse U. Akarca, BSc, Shimobi Onuoha, PhD, David Cole, PhD, Andrew Sewell, PhD, Karl S Peggs, MD, David C. Linch, MD MRCP, MB BCh, BA, Teresa Marafioti, MD, Martin A Pule, MD PhD

Blood (2016) 128 (22): 811.

https://doi.org/10.1182/blood.V128.22.811.811

Published: 2016

Journal Articles

Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells.

Martin A. Pule, MD, Alexandra Rousseau, MD, Elizabeth Kang, MD, Takahiro Ueda, MD, Christof von Kalle, Arthur W. Nienhuis, MD, Helen Heslop, MD, Elio Vanin, PhD, John F. Tisdale, MD

Blood (2004) 104 (11): 2102.

https://doi.org/10.1182/blood.V104.11.2102.2102

Published: 2004

Journal Articles

Flanking-Sequence Exponential Anchored (FLEA) PCR - a Sensitive and Highly Specific Method for Detecting Retroviral Integrant-Host-Junction Sequences.

Martin A. Pule, MD, Alexandra Rousseau, MD, Elio F. Vanin, PhD, Malcolm K. Brenner, MD, PhD, Helen E. Heslop, MD, PhD

Blood (2004) 104 (11): 2112.

https://doi.org/10.1182/blood.V104.11.2112.2112

Published: 2004

Journal Articles

Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells.

Karin C. Straathof, MD, Martin A. Pule, MD, Patricia Yotnda, PhD, Gianpietro Dotti, MD, Elio F. Vanin, PhD, Malcolm K. Brenner, MD, PhD, Helen E. Heslop, MD, PhD, David M. Spencer, PhD, Cliona M. Rooney, PhD

Blood (2004) 104 (11): 1743.

https://doi.org/10.1182/blood.V104.11.1743.1743

Published: 2004

Journal Articles

Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-ζ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.

Martin A. Pule, MD, Karin C. Straathof, MD, Gianpietro Dotti, MD, Helen E. Heslop, MD, PhD, Cliona M. Rooney, PhD, Malcolm K. Brenner, MD, PhD

Blood (2004) 104 (11): 1747.

https://doi.org/10.1182/blood.V104.11.1747.1747

Published: 2004

NARROW

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

Construction and Pre-Clinical Evaluation of a New Anti-CD19 Chimeric Antigen Receptor

Novel Humanised ROR1 Chimeric Antigen Receptors for the Treatment of Haematological Malignancies

An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells.

Flanking-Sequence Exponential Anchored (FLEA) PCR - a Sensitive and Highly Specific Method for Detecting Retroviral Integrant-Host-Junction Sequences.

Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells.

Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-ζ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only